These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20148097)

  • 1. The effect of bangerter occlusion foils on blepharospasm and hemifacial spasm in occlusion-positive and occlusion-negative patients.
    Malhotra R; Then SY; Richards A; Cheek E
    Open Ophthalmol J; 2010 Jan; 4():1-6. PubMed ID: 20148097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative absence of psychopathology in benign essential blepharospasm and hemifacial spasm.
    Scheidt CE; Schuller B; Rayki O; Kommerell G; Deuschl G
    Neurology; 1996 Jul; 47(1):43-5. PubMed ID: 8710122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexistent blepharospasm and hemifacial spasm: overlapping pathophysiologic mechanism?
    Tan EK; Chan LL; Koh KK
    J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):494-6. PubMed ID: 14966174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm.
    Lai KKH; Tsang A; Kuk AKT; Ko CKL; Chan E; Ko STC
    Neuroophthalmology; 2021; 45(5):293-300. PubMed ID: 34566211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benign essential blepharospasm: risk factors with reference to hemifacial spasm.
    Hall TA; McGwin G; Searcey K; Xie A; Hupp SL; Owsley C; Kline LB
    J Neuroophthalmol; 2005 Dec; 25(4):280-5. PubMed ID: 16340493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Closely spaced stressful life events precede the onset of benign essential blepharospasm and hemifacial spasm.
    Johnson LN; Lapour RW; Johnson GM; Johnson PJ; Madsen RW; Hackley SA
    J Neuroophthalmol; 2007 Dec; 27(4):275-80. PubMed ID: 18090560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
    Alexandru H; Muthuraman M; Chirumamilla VC; Koirala N; Paktas B; Deuschl G; Zeuner KE; Groppa S
    PLoS One; 2016; 11(12):e0168652. PubMed ID: 27992533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm.
    Hall TA; McGwin G; Searcey K; Xie A; Hupp SL; Owsley C; Kline LB
    Arch Ophthalmol; 2006 Jan; 124(1):116-9. PubMed ID: 16401794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which factors impact on quality of life for adults with blepharospasm and hemifacial spasm?
    Lawes-Wickwar S; McBain H; Hirani SP; Hurt CS; Dunlop N; Solly D; Crampton B; Newman SP; Ezra DG
    Orbit; 2021 Apr; 40(2):110-119. PubMed ID: 32116098
    [No Abstract]   [Full Text] [Related]  

  • 11. Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm.
    Dong H; Fan S; Luo Y; Peng B
    Neuropsychiatr Dis Treat; 2019; 15():33-36. PubMed ID: 30587995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW; Fang PC; Chao TL; Chien CC; Kuo MT
    Sci Rep; 2018 May; 8(1):8367. PubMed ID: 29849166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
    Lolekha P; Choolam A; Kulkantrakorn K
    Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facial dystonias and rosacea: is there an association?
    Khan TT; Donaldson J; Hesse RJ
    Orbit; 2014 Aug; 33(4):276-9. PubMed ID: 24831933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes following a break in ophthalmic botulinum toxin therapy during the COVID-19 pandemic.
    Jamison A; Favor M; Malhotra R
    Can J Ophthalmol; 2024 Feb; 59(1):e41-e45. PubMed ID: 36372133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Blepharospasm/Hemifacial Spasm.
    Green KE; Rastall D; Eggenberger E
    Curr Treat Options Neurol; 2017 Sep; 19(11):41. PubMed ID: 28965229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FL-41 tint improves blink frequency, light sensitivity, and functional limitations in patients with benign essential blepharospasm.
    Blackburn MK; Lamb RD; Digre KB; Smith AG; Warner JE; McClane RW; Nandedkar SD; Langeberg WJ; Holubkov R; Katz BJ
    Ophthalmology; 2009 May; 116(5):997-1001. PubMed ID: 19410958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemodenervation for the Treatment of Facial Dystonia: A Report by the American Academy of Ophthalmology.
    Bilyk JR; Yen MT; Bradley EA; Wladis EJ; Mawn LA
    Ophthalmology; 2018 Sep; 125(9):1459-1467. PubMed ID: 29653859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Injection Botulinum Toxin in Blepharospasm.
    Amatya M; Limbu B; Sthapit PR; Gurung HB; Saiju R
    Nepal J Ophthalmol; 2021 Jan; 13(25):40-49. PubMed ID: 33981096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An investigation into quality of life improvement in patients undergoing microvascular decompression for hemifacial spasm.
    Lawrence JD; Frederickson AM; Chang YF; Weiss PM; Gerszten PC; Sekula RF
    J Neurosurg; 2018 Jan; 128(1):193-201. PubMed ID: 28186450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.